PMID- 12200356
OWN - NLM
STAT- MEDLINE
DCOM- 20021024
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 100
IP  - 6
DP  - 2002 Sep 15
TI  - Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and 
      HIV infection.
PG  - 1984-8
AB  - A phase 2 prospective study was performed to evaluate the feasibility and 
      activity of a short, dose-intensive chemotherapy regimen and radiotherapy (the 
      Stanford V regimen) plus highly active antiretroviral therapy (HAART) and 
      granulocyte colony-stimulating factor (G-CSF) support in patients with Hodgkin 
      disease and HIV infection. Fifty-nine patients were enrolled. Stanford V was well 
      tolerated and 69% of the patients completed treatment with no dose reduction or 
      delayed chemotherapy administration. The most important dose-limiting side 
      effects were bone marrow toxicity and neurotoxicity. Complete remission was 
      achieved by 81% of the patients, and after a median follow-up of 17 months 33 
      patients (56%) were alive and disease-free. The estimated 3-year overall survival 
      (OS), disease-free survival (DFS), and freedom from progression (FFP) were 51%, 
      68%, and 60%, respectively. Probability of FFP was significantly (P =.02) higher 
      among patients with an International Prognostic Score (IPS) of 2 or lower than in 
      those with an IPS higher than 2, and the percentages of FFP at 2 years in these 
      groups were 83% and 41%, respectively. Similarly, the probability of OS was 
      significantly (P =.0004) different in the 2 groups, and the percentages of OS at 
      3 years were 76% and 33%, respectively. Our data confirm that the Stanford V 
      regimen with concomitant HAART is feasible and active in an HIV setting. However, 
      a more intensive approach should be considered in patients with high IPSs.
FAU - Spina, Michele
AU  - Spina M
AD  - Division of Medical Oncology A, National Cancer Institute, Via Pedemontana 
      Occidentale 12, 33081 Aviano (PN), Italy.
FAU - Gabarre, Jean
AU  - Gabarre J
FAU - Rossi, Giuseppe
AU  - Rossi G
FAU - Fasan, Marco
AU  - Fasan M
FAU - Schiantarelli, Clara
AU  - Schiantarelli C
FAU - Nigra, Ezio
AU  - Nigra E
FAU - Mena, Maurizio
AU  - Mena M
FAU - Antinori, Andrea
AU  - Antinori A
FAU - Ammassari, Adriana
AU  - Ammassari A
FAU - Talamini, Renato
AU  - Talamini R
FAU - Vaccher, Emanuela
AU  - Vaccher E
FAU - di Gennaro, Giampiero
AU  - di Gennaro G
FAU - Tirelli, Umberto
AU  - Tirelli U
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 11056-06-7 (Bleomycin)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - VB0R961HZT (Prednisone)
RN  - Stanford V protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use/toxicity
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - Bleomycin/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Etoposide/administration & dosage
MH  - HIV Infections/complications/*drug therapy/mortality
MH  - HIV-1
MH  - Hodgkin Disease/*drug therapy/mortality/virology
MH  - Humans
MH  - Lymphoma, AIDS-Related/*drug therapy/mortality
MH  - Male
MH  - Mechlorethamine/administration & dosage
MH  - Middle Aged
MH  - Prednisone/administration & dosage
MH  - Prognosis
MH  - Prospective Studies
MH  - Remission Induction/methods
MH  - Survival Analysis
MH  - Survival Rate
MH  - Vinblastine/administration & dosage
MH  - Vincristine/administration & dosage
EDAT- 2002/08/30 10:00
MHDA- 2002/10/31 04:00
CRDT- 2002/08/30 10:00
PHST- 2002/08/30 10:00 [pubmed]
PHST- 2002/10/31 04:00 [medline]
PHST- 2002/08/30 10:00 [entrez]
AID - S0006-4971(20)50993-2 [pii]
AID - 10.1182/blood-2002-03-0989 [doi]
PST - ppublish
SO  - Blood. 2002 Sep 15;100(6):1984-8. doi: 10.1182/blood-2002-03-0989.